OS Therapies names Kerry Clem as CCO, Frank Knuettel II as CFO

OS Therapies, Inc. (NYSE American: OSTX) said its board appointed Francis (Frank) Knuettel II as Chief Financial Officer and Kerry Clem as Chief Commercial Officer, effective September 29, 2026¹. In connection with the move, Christopher P. Acevedo ceased serving as Chief Financial Officer of the Company and will continue to provide services to the Company in a consulting capacity¹.

The company said Clem will oversee commercialization planning for Herlystic, its investigational therapy aimed at preventing or delaying recurrence in patients with fully resected, pulmonary metastatic osteosarcoma¹. His duties are described as developing the commercial organization and launch infrastructure, assessing patient and treatment-center needs, and preparing for potential U.S. market entry, subject to regulatory approval¹.

On regulatory timing, the company said it plans to launch Herlystic first in the United States once approved in the U.S., U.K., and Europe, though it expects the U.K.'s MHRA to issue a decision before the FDA or EMA¹. It is pursuing an MHRA Conditional Marketing Authorization Application under Project Orbis via the Innovative Licensing and Access Pathway, with submission targeted for early in the fourth quarter of 2026¹, alongside plans for a U.S. BLA under the Accelerated Approval pathway and a parallel European CMAA¹.

Knuettel's background includes serving as CFO and later CEO of Channel Therapeutics Corporation from June 2022, then CFO of Pelthos Therapeutics following Channel's 2025 merger with LNHC, Inc., through April 2026¹. His employment agreement runs an initial three-year term commencing September 29, 2026¹, with a base salary of $300,000 per year, rising to $360,000 after a qualifying material transaction¹.

Clem most recently was Chief Commercial Officer of Solaxa Inc. from August 2024 to July 2025, and also its CEO from August 2025 to May 2026¹. His agreement likewise runs an initial three-year term from September 29, 2026, with a $300,000 base salary¹.

Separately, the company disclosed receiving over $3 million in non-dilutive capital from U.K. VAT refunds and accruing over $7 million in R&D tax credits¹, and said it had agreed with its largest vendors to delay the majority of outstanding accounts payable until the second quarter of 2027¹.